{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:48:42Z","timestamp":1760852922834},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2003,6,24]],"date-time":"2003-06-24T00:00:00Z","timestamp":1056412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,6,24]],"date-time":"2003-06-24T00:00:00Z","timestamp":1056412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2003,7,1]]},"DOI":"10.1038\/sj.jhh.1001576","type":"journal-article","created":{"date-parts":[[2003,6,24]],"date-time":"2003-06-24T10:36:38Z","timestamp":1056450998000},"page":"505-511","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Why not prescribe the best drugs for hypertension now?"],"prefix":"10.1038","volume":"17","author":[{"given":"S Y S","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G T","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T M","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,6,24]]},"reference":[{"key":"BF1001576_CR1","doi-asserted-by":"crossref","unstructured":"Colhoun HM, Dong W, Poulter NR . Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16: 747\u2013572.","DOI":"10.1097\/00004872-199816060-00005"},{"key":"BF1001576_CR2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0140-6736(99)80004-X","volume":"354","author":"R Horton","year":"1999","unstructured":"Horton R . Future of European cardiology: continentally isolated or globally integrated? Lancet 1999; 354: 791\u2013792.","journal-title":"Lancet"},{"key":"BF1001576_CR3","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S0140-6736(96)07493-4","volume":"349","author":"CJ Murray","year":"1997","unstructured":"Murray CJ, Lopez AD . Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269\u20131276.","journal-title":"Lancet"},{"key":"BF1001576_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/oxfordjournals.bmb.a072892","volume":"50","author":"R Collins","year":"1994","unstructured":"Collins R, MacMahon S . Blood pressure, antihyper-tensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272\u2013298.","journal-title":"Br Med Bull"},{"key":"BF1001576_CR5","doi-asserted-by":"crossref","unstructured":"Blood Pressure Lowering Treatment Trialist' Collaboration. Effects of ACE inhibitors, calcium antagonist, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355: 1955\u20131964.","DOI":"10.1016\/S0140-6736(00)03307-9"},{"key":"BF1001576_CR6","doi-asserted-by":"crossref","unstructured":"The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413\u20132446.","DOI":"10.1001\/archinte.157.21.2413"},{"key":"BF1001576_CR7","doi-asserted-by":"crossref","unstructured":"1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151\u2013183.","DOI":"10.1097\/00004872-199917020-00001"},{"key":"BF1001576_CR8","first-page":"1147","volume":"16","author":"NM Kaplan","year":"2000","unstructured":"Kaplan NM . Guidelines for the management of hypertension. Can J Cardiol 2000; 16: 1147\u20131152.","journal-title":"Can J Cardiol"},{"key":"BF1001576_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/sj.jhh.1000917","volume":"13","author":"L Ramsay","year":"1999","unstructured":"Ramsay L et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569\u2013592.","journal-title":"J Hum Hypertens"},{"key":"BF1001576_CR10","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). Hypertension in older people. A national clinical guideline. 2001 SIGN publication no. 49."},{"key":"BF1001576_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1161\/01.HYP.25.3.305","volume":"25","author":"VL Burt","year":"1995","unstructured":"Burt VL et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988\u20131991. Hypertension 1995; 25: 305\u2013313.","journal-title":"Hypertension"},{"key":"BF1001576_CR12","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755\u20131762.","journal-title":"Lancet"},{"key":"BF1001576_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/bmj.323.7305.142","volume":"323","author":"R Nuesch","year":"2001","unstructured":"Nuesch R et al. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case\u2013control study. BMJ 2001; 323: 142\u2013146.","journal-title":"BMJ"},{"key":"BF1001576_CR14","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1097\/00004872-199917070-00022","volume":"17","author":"B Waeber","year":"1999","unstructured":"Waeber B, Leonetti G, Kolloch R, McInnes GT . Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens 1999; 17: 1041\u20131045.","journal-title":"J Hypertens"},{"key":"BF1001576_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1056\/NEJMoa010273","volume":"345","author":"DJ Hyman","year":"2001","unstructured":"Hyman DJ, Pavlik VN . Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345: 479\u2013486.","journal-title":"N Engl J Med"},{"key":"BF1001576_CR16","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","volume":"354","author":"L Hansson","year":"1999","unstructured":"Hansson L et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751\u20131756.","journal-title":"Lancet"},{"key":"BF1001576_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611\u2013616.","journal-title":"Lancet"},{"key":"BF1001576_CR18","doi-asserted-by":"crossref","unstructured":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events on hypertensive patients randomised to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967\u20131975.","DOI":"10.1001\/jama.283.15.1967"},{"key":"BF1001576_CR19","doi-asserted-by":"crossref","unstructured":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981\u20132997.","DOI":"10.1001\/jama.288.23.2981"},{"key":"BF1001576_CR20","doi-asserted-by":"crossref","unstructured":"Wing LMH et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 835\u2013592.","DOI":"10.1056\/NEJMoa021716"},{"key":"BF1001576_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM199803053381003","volume":"338","author":"RO Estacio","year":"1998","unstructured":"Estacio RO et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645\u2013652.","journal-title":"N Engl J Med"},{"key":"BF1001576_CR22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2337\/diacare.21.4.597","volume":"21","author":"P Tatti","year":"1998","unstructured":"Tatti P et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597\u2013603.","journal-title":"Diabetes Care"},{"key":"BF1001576_CR23","doi-asserted-by":"publisher","first-page":"888","DOI":"10.2337\/diacare.23.7.888","volume":"23","author":"M Pahor","year":"2000","unstructured":"Pahor M et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000; 23: 888\u2013892.","journal-title":"Diabetes Care"},{"key":"BF1001576_CR24","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456\u20131462.","journal-title":"N Engl J Med"},{"key":"BF1001576_CR25","doi-asserted-by":"crossref","unstructured":"HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145\u2013153.","DOI":"10.1056\/NEJM200001203420301"},{"key":"BF1001576_CR26","doi-asserted-by":"crossref","unstructured":"PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or tra-nsient ischaemic attack. Lancet 2001; 358: 1033\u20131041.","DOI":"10.1016\/S0140-6736(01)06178-5"},{"key":"BF1001576_CR27","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","volume":"333","author":"L Kober","year":"1995","unstructured":"Kober L et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670\u20131676.","journal-title":"N Engl J Med"},{"key":"BF1001576_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/18.suppl_B.35","volume":"18","author":"JG Cleland","year":"1997","unstructured":"Cleland JG et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 1997; 18: 41\u201351.","journal-title":"Eur Heart J"},{"key":"BF1001576_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jama.286.4.421","volume":"286","author":"HC Gerstein","year":"2001","unstructured":"Gerstein HC et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421\u2013426.","journal-title":"JAMA"},{"key":"BF1001576_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.7326\/0003-4819-135-2-200107170-00015","volume":"135","author":"RW Schrier","year":"2001","unstructured":"Schrier RW, Estacio RO . The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials. Ann Intern Med 2001; 135: 138\u2013139.","journal-title":"Ann Intern Med"},{"key":"BF1001576_CR31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0895-7061(01)01307-3","volume":"14","author":"GS Stergiou","year":"2001","unstructured":"Stergiou GS et al. Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response to angiotensin receptor antagonism? Am J Hypertens 2001; 14: 688\u2013693.","journal-title":"Am J Hypertens"},{"key":"BF1001576_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0895-7061(00)01214-0","volume":"14","author":"R Fogari","year":"2001","unstructured":"Fogari R et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14: 27\u201331.","journal-title":"Am J Hypertens"},{"key":"BF1001576_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/00000441-200105000-00006","volume":"321","author":"JL Llisterri","year":"2001","unstructured":"Llisterri JL et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336\u2013341.","journal-title":"Am J Med Sci"},{"key":"BF1001576_CR34","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","volume":"285","author":"LY Agodoa","year":"2001","unstructured":"Agodoa LY et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a ran-domized controlled trial. JAMA 2001; 285: 2719\u20132728.","journal-title":"JAMA"},{"key":"BF1001576_CR35","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995\u20131003.","journal-title":"Lancet"},{"key":"BF1001576_CR36","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","volume":"359","author":"LH Lindholm","year":"2002","unstructured":"Lindholm LH et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004\u20131010.","journal-title":"Lancet"},{"key":"BF1001576_CR37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","volume":"27","author":"S Yusuf","year":"1985","unstructured":"Yusuf S et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335\u2013371.","journal-title":"Prog Cardiovasc Dis"},{"key":"BF1001576_CR38","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt B et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582\u20131587.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"BF1001576_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000047284","volume":"91","author":"JN Cohn","year":"1999","unstructured":"Cohn JN . Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial. Cardiology 1999; 91(Suppl 1): 19\u201322.","journal-title":"Cardiology"},{"key":"BF1001576_CR40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/080370598437394","volume":"7","author":"J Mann","year":"1998","unstructured":"Mann J, Julius S . The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardio-vascular events in hypertension. Rationale and design. Blood Press 1998; 7:176\u2013183.","journal-title":"Blood Press"},{"key":"BF1001576_CR41","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861\u2013869.","journal-title":"N Engl J Med"},{"key":"BF1001576_CR42","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870\u2013878.","journal-title":"N Engl J Med"},{"key":"BF1001576_CR43","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851\u2013860.","journal-title":"N Engl J Med"},{"key":"BF1001576_CR44","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","volume":"321","author":"CE Mogensen","year":"2000","unstructured":"Mogensen CE et al. Randomised controlled trial of dual blockade of renin\u2013angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440\u20131444.","journal-title":"BMJ"},{"key":"BF1001576_CR45","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","volume":"106","author":"G Viberti","year":"2002","unstructured":"Viberti G, Wheeldon NM . MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672\u2013678.","journal-title":"Circulation"},{"key":"BF1001576_CR46","doi-asserted-by":"publisher","first-page":"141A","DOI":"10.1016\/S0895-7061(99)80501-9","volume":"12","author":"RW Schrier","year":"1999","unstructured":"Schrier RW et al. Appropriate Blood pressure Control in Diabetes-part 2 with Valsartan (ABCD-2V trial). Am J Hypertens 1999; 12: 141A.","journal-title":"Am J Hypertens"},{"key":"BF1001576_CR47","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","volume":"360","author":"K Dickstein","year":"2002","unstructured":"Dickstein K, Kjekshus J . OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotension II Antagonist Losartan. Lancet 2002; 360: 752\u2013760.","journal-title":"Lancet"},{"key":"BF1001576_CR48","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1067\/mhj.2000.108832","volume":"140","author":"MA Pfeffer","year":"2000","unstructured":"Pfeffer MA et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000; 140: 727\u2013750.","journal-title":"Am Heart J"},{"key":"BF1001576_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1185\/03007999909115168","volume":"15","author":"L Argenziano","year":"1999","unstructured":"Argenziano L, Trimarco B . Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multi-national Study Group. Curr Med Res Opin 1999; 15: 9\u201314.","journal-title":"Curr Med Res Opin"},{"key":"BF1001576_CR50","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1001\/jama.284.10.1297","volume":"284","author":"DR Lichtenstein","year":"2000","unstructured":"Lichtenstein DR, Wolfe MM . COX-2-selective NSAIDs: new and improved? JAMA 2000; 284: 1297\u20131299.","journal-title":"JAMA"},{"key":"BF1001576_CR51","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1136\/bmj.322.7292.989","volume":"322","author":"N Freemantle","year":"2001","unstructured":"Freemantle N . Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? BMJ 2001; 322: 989\u2013991.","journal-title":"BMJ"},{"key":"BF1001576_CR52","doi-asserted-by":"crossref","unstructured":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383\u20131389.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"BF1001576_CR53","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301\u20131307.","journal-title":"N Engl J Med"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1001576.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001576","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001576.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T15:28:41Z","timestamp":1647530921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1001576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,24]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,7,1]]}},"alternative-id":["BF1001576"],"URL":"https:\/\/doi.org\/10.1038\/sj.jhh.1001576","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,24]]},"assertion":[{"value":"26 July 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2003","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2003","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2003","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}